Derry Sheena, Karlin Samuel M, Moore R Andrew
Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
Cochrane Database Syst Rev. 2015 Feb 5;2015(2):CD010107. doi: 10.1002/14651858.CD010107.pub3.
This is an update of the original Cochrane review published in Issue 3, 2013. There is good evidence that combining two different analgesics in fixed doses in a single tablet can provide better pain relief in acute pain and headache than either drug alone, and that the drug-specific effects are essentially additive. This appears to be broadly true in postoperative pain and migraine headache across a range of different drug combinations and when tested in the same and different trials. Some combinations of ibuprofen and codeine are available without prescription (but usually only from a pharmacy) where the dose of codeine is lower, and with a prescription when the dose of codeine is higher.Use of combination analgesics that contain codeine has been a source of some concern because of misuse from over-the-counter preparations.
To assess the analgesic efficacy and adverse effects of a single oral dose of ibuprofen plus codeine for acute moderate-to-severe postoperative pain using methods that permit comparison with other analgesics evaluated in standardised trials using almost identical methods and outcomes.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Oxford Pain Relief Database, ClinicalTrials.gov, and the reference lists of articles. The date of the most recent search was 1 December 2014.
Randomised, double-blind, placebo- or active-controlled clinical trials of single dose oral ibuprofen plus codeine for acute postoperative pain in adults.
Two review authors independently considered trials for inclusion in the review, assessed risk of bias, and extracted data. We used the area under the pain relief versus time curve to derive the proportion of participants prescribed ibuprofen plus codeine, placebo, or the same dose of ibuprofen alone with at least 50% pain relief over six hours, using validated equations. We calculated the risk ratio (RR) and number needed to treat to benefit (NNT). We used information on the use of rescue medication to calculate the proportion of participants requiring rescue medication and the weighted mean of the median time to use. We also collected information on adverse effects. Analyses were planned for different doses of ibuprofen and codeine, but especially for codeine where we set criteria for low (< 10 mg), medium (10 to 20 mg), and high (> 20 mg) doses.
Since the last version of this review no new studies were found. Information was available from six studies with 1342 participants, using a variety of doses of ibuprofen and codeine. In four studies (443 participants) using ibuprofen 400 mg plus codeine 25.6 mg to 60 mg (high dose codeine) 64% of participants had at least 50% maximum pain relief with the combination compared to 18% with placebo. The NNT was 2.2 (95% confidence interval 1.8 to 2.6) (high quality evidence). In three studies (204 participants) ibuprofen plus codeine (any dose) was better than the same dose of ibuprofen (69% versus 55%) but the result was barely significant with a relative benefit of 1.3 (1.01 to 1.6) (moderate quality evidence). In two studies (159 participants) ibuprofen plus codeine appeared to be better than the same dose of codeine alone (69% versus 33%), but no analysis was done. There was no difference between the combination and placebo in the reporting of adverse events in these acute studies (moderate quality evidence).
AUTHORS' CONCLUSIONS: The combination of ibuprofen 400 mg plus codeine 25.6 mg to 60 mg demonstrates good analgesic efficacy. Very limited data suggest that the combination is better than the same dose of either drug alone, and that similar numbers of people experience adverse events with the combination as with placebo.
这是对2013年第3期发表的原始Cochrane系统评价的更新。有充分证据表明,将两种不同的镇痛药以固定剂量制成单片复方制剂,在缓解急性疼痛和头痛方面比单独使用任何一种药物效果更好,且药物的特定效应基本具有相加性。在术后疼痛和偏头痛中,一系列不同的药物组合在相同和不同试验中进行测试时,情况似乎大致如此。一些布洛芬和可待因的复方制剂无需处方即可获得(但通常仅从药房购买),其中可待因剂量较低,而可待因剂量较高时则需凭处方购买。由于非处方制剂的滥用,含可待因的复方镇痛药的使用一直受到一些关注。
采用与使用几乎相同方法和结局的标准化试验中评估的其他镇痛药进行比较的方法,评估单剂量口服布洛芬加可待因治疗急性中度至重度术后疼痛的镇痛效果和不良反应。
我们检索了Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE、牛津疼痛缓解数据库、ClinicalTrials.gov以及文章的参考文献列表。最近一次检索日期为2014年12月1日。
单剂量口服布洛芬加可待因治疗成人急性术后疼痛的随机、双盲、安慰剂对照或活性药物对照临床试验。
两名综述作者独立考虑纳入综述的试验,评估偏倚风险并提取数据。我们使用疼痛缓解与时间曲线下的面积,通过验证方程得出服用布洛芬加可待因、安慰剂或相同剂量布洛芬单药的参与者在6小时内疼痛缓解至少50%的比例。我们计算了风险比(RR)和需治疗获益人数(NNT)。我们利用急救药物使用信息计算需要急救药物的参与者比例以及使用时间中位数的加权平均值。我们还收集了不良反应信息。计划对不同剂量的布洛芬和可待因进行分析,特别是针对可待因,我们设定了低剂量(<10mg)、中剂量(10至20mg)和高剂量(>20mg)的标准。
自本综述的上一版本以来,未发现新的研究。六项研究纳入了1342名参与者,使用了多种剂量的布洛芬和可待因。在四项研究(443名参与者)中,使用布洛芬400mg加可待因25.6mg至60mg(高剂量可待因),64%的参与者使用该复方制剂后最大疼痛缓解至少50%,而安慰剂组为18%。NNT为2.2(95%置信区间1.8至2.6)(高质量证据)。在三项研究(204名参与者)中,布洛芬加可待因(任何剂量)优于相同剂量的布洛芬(69%对55%),但结果勉强显著,相对获益为1.3(1.01至1.6)(中等质量证据)。在两项研究(159名参与者)中,布洛芬加可待因似乎优于相同剂量的可待因单药(69%对33%),但未进行分析。在这些急性研究中,复方制剂与安慰剂在不良事件报告方面无差异(中等质量证据)。
布洛芬400mg加可待因25.6mg至60mg的复方制剂显示出良好的镇痛效果。非常有限的数据表明,该复方制剂优于相同剂量的任何一种单药,且使用复方制剂和安慰剂出现不良事件的人数相似。